Association between caffeine intake and age at onset in Huntington’s disease
Neurobiology of Disease. 2013-10-01; 58: 179-182
DOI: 10.1016/J.NBD.2013.05.013
Read on PubMed
1. Neurobiol Dis. 2013 Oct;58:179-82. doi: 10.1016/j.nbd.2013.05.013. Epub 2013 May
31.
Association between caffeine intake and age at onset in Huntington’s disease.
Simonin C(1), Duru C, Salleron J, Hincker P, Charles P, Delval A, Youssov K,
Burnouf S, Azulay JP, Verny C, Scherer C, Tranchant C, Goizet C, Debruxelles S,
Defebvre L, Sablonnière B, Romon-Rousseaux M, Buée L, Destée A, Godefroy O, Dürr
A, Landwehrmeyer B; REGISTRY Study of the European Huntington’s Disease Network,
Bachoud-Levi AC, Richard F, Blum D, Krystkowiak P; Huntington French Speaking
Network.
Author information:
(1)Department of Neurology and Movement Disorders, Roger Salengro University
Hospital, Lille, France.
Habitual consumption of caffeine, a non-selective adenosine receptor (AR)
antagonist, has been suggested to be beneficial in Parkinson’s and Alzheimer’s
diseases. Experimental evidence support that ARs play a role in Huntington’s
disease (HD) raising the hypothesis that caffeine may be a life-style modifier in
HD. To determine a possible relationship between caffeine consumption and age at
onset (AAO) in HD, we retrospectively assessed caffeine consumption in 80 HD
patients using a dietary survey and determined relationship with AAO. Following
adjustment for gender, smoking status and CAG repeat length, caffeine consumption
greater than 190mg/day was significantly associated with an earlier AAO. These
data support an association between habitual caffeine intake and AAO in HD
patients, but further studies are warranted to understand the link between these
variables.
Copyright © 2013 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.nbd.2013.05.013
PMID: 23732677 [Indexed for MEDLINE]